文献速递骨软组织肉瘤与黑色素瘤

黑色素瘤前哨淋巴结阳性风险预测计算器的改进:澳大利亚黑色素瘤研究所列线图

Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram.
PubMed 文献 · J Clin Oncol · 2020-06-12

该研究基于3477例在澳大利亚黑色素瘤研究所接受前哨淋巴结活检的黑色素瘤患者数据,开发了新的列线图,用核分裂率、黑色素瘤亚型和淋巴血管侵犯替代MSKCC模型中的身体部位和Clark分级。新模型预测准确性为73.9%,较MSKCC模型的67.7%提高9.2%(P < .001),外部验证C统计量为75.0%。

要点

  • MIA列线图预测前哨淋巴结阳性准确性73.9%,优于MSKCC模型的67.7%。
  • 新模型仅需6个广泛可用的临床病理参数即可在线计算风险。
  • 使用MIA模型可减少22.1%前哨淋巴结阴性患者的不必要活检,且不损失敏感性。

核心结论

  • 开发了一个稳健的列线图,比现有方法更准确地估计黑色素瘤患者前哨淋巴结阳性风险。
  • 该模型仅需输入6个广泛可用的临床病理参数。
  • 与MSKCC列线图或NCCN/ASCO/SSO指南相比,使用该模型可显著减少不必要的前哨淋巴结活检数量,且不损失敏感性。

研究设计与样本

  • 基于3477例在澳大利亚黑色素瘤研究所接受前哨淋巴结活检的黑色素瘤患者数据开发新列线图。
  • 用核分裂率、黑色素瘤亚型和淋巴血管侵犯替代MSKCC模型中的身体部位和Clark分级。
  • 使用德克萨斯大学MD安德森癌症中心3496例患者数据进行外部验证。

主要发现

  • MSKCC模型ROC曲线预测准确性为67.7%(95% CI,65.3%至70.0%)。
  • MIA模型预测准确性为73.9%(95% CI,71.9%至75.9%),较MSKCC模型提高9.2%(P < .001)。
  • 在2748例前哨淋巴结阴性患者中,基于MIA模型、MSKCC模型和NCCN或ASCO/SSO标准,分别有22.1%、13.4%和12.4%的患者不会接受前哨淋巴结活检。
  • 外部验证C统计量为75.0%(95% CI,73.2%至76.7%)。

临床怎么用

  • 临床可使用在线计算器(www.melanomarisk.org.au)输入6个临床病理参数评估黑色素瘤患者前哨淋巴结阳性风险。
  • 该工具可辅助筛选前哨淋巴结活检患者,减少不必要活检且不损失敏感性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: For patients with primary cutaneous melanoma, the risk of sentinel node (SN) metastasis varies according to several clinicopathologic parameters. Patient selection for SN biopsy can be assisted by National Comprehensive Cancer Network (NCCN) and ASCO/Society of Surgical Oncology (SSO) guidelines and the Memorial Sloan Kettering Cancer Center (MSKCC) online nomogram. We sought to develop an improved online risk calculator using alternative clinicopathologic parameters to more accurately predict SN positivity. PATIENTS AND METHODS: Data from 3,477 patients with melanoma who underwent SN biopsy at Melanoma Institute Australia (MIA) were analyzed. A new nomogram was developed by replacing body site and Clark level from the MSKCC model with mitotic rate, melanoma subtype, and lymphovascular invasion. The predictive performance of the new nomogram was externally validated using data from The University of Texas MD Anderson Cancer Center (n = 3,496). RESULTS: The MSKCC model receiver operating characteristic curve had a predictive accuracy of 67.7% (95% CI, 65.3% to 70.0%). The MIA model had a predictive accuracy of 73.9% (95% CI, 71.9% to 75.9%), a 9.2% increase in accuracy over the MSKCC model (P < .001). Among the 2,748 SN-negative patients, SN biopsy would not have been offered to 22.1%, 13.4%, and 12.4% based on the MIA model, the MSKCC model, and NCCN or ASCO/SSO criteria, respectively. External validation generated a C-statistic of 75.0% (95% CI, 73.2% to 76.7%). CONCLUSION: A robust nomogram was developed that more accurately estimates the risk of SN positivity in patients with melanoma than currently available methods. The model only requires the input of 6 widely available clinicopathologic parameters. Importantly, the number of patients undergoing unnecessary SN biopsy would be significantly reduced compared with use of the MSKCC nomogram or the NCCN or ASCO/SSO guidelines, without losing sensitivity. An online calculator is available at www.melanomarisk.org.au.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lo SN, Ma J, Scolyer RA, et al. Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. J Clin Oncol. 2020. PMID: 32530761. doi:10.1200/JCO.19.02362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。